Biologic therapy in psoriasis

From: Indian Journal of Dermatology, Venereology and Leprology | Date: July 1, 2006| Author: Dogra, Alka; Sachdeva, Silonie | Copyright information

Introduction

Psoriasis is a common, chronic, disfiguring, inflammatory and proliferative condition of the skin, involving both genetic and environmental factors to play an important role. It is associated with significant morbidity, with 20-30% of the patients having severe disease.[1] Most of the traditional therapies available till now, aim at producing clinical improvement of the disease without targeting the factors that cause psoriasis. The recent advances in immunology based upon...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

Biologics are showing efficacy in pediatric psoriasis patients.(Dermatologic Therapy)
Skin & Allergy News ; ... to discontinue etanercept therapy. (One developed aseptic meningitis ... able to interrupt etanercept therapy and restart after the infections ... of etanercept for pediatric psoriasis. Results suggest that subcutaneous ... events were seen. Stopping therapy in patients whose psoriasis cleared ...
Psoriasis biologics show different efficacy rates.(Dermatologic Therapy)
Skin & Allergy News ; ... Infliximab is the most effective biologic agent for psoriasis, whether you look at hard data ... efficacy data for the three biologic agents approved for psoriasis treatment--alefacept (Amevive ... Enbrel)--with data on two newer biologic agents in the pipeline for approval ... study comparing ...
Combination biologics therapies may offer safer psoriasis option
Dermatology Times ; ... finding that combining biologic therapies with other medications ... effective - and safest - psoriasis therapy when patients do not respond ... the data we have so far, biologic drugs appear to be substantially ... involved in the development of psoriasis. Biologic agents ...
Efalizumab: A new biologic therapy for the control of chronic plaque psoriasis
Formulary ; ... in the treatment of chronic moderate-to-severe plaque psoriasis in adults aged 18 years and older. Efalizumab does not ... more rapid onset of action (significant improvements in Psoriasis Area and Severity Index [PASI] response after 2 doses ... efalizumab will likely compete with another approved biologic, ...
Recent developments in T-cell-specific biologic therapy for the treatment of psoriasis
Dermatology Times ; ... developments in the treatment of psoriasis. Recently, an entirely new approach to therapy has been made possible as ... of the pathophysiology of psoriasis. Four new biologic therapy agents are currently available or in development to treat psoriasis. Two of these agents ...